 Home > Active Ingredient News > Immunology News > Do a good job in CVD risk management of RA patients, it is important to choose the right drug!

Do a good job in CVD risk management of RA patients, it is important to choose the right drug!

 Last Update: 2022-09-15
 Source: Internet
 Author: User

Tags

hypertension

meconium aspiration syndrome treatment

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

*For medical professionals only

To treat RA, we must go to

Rheumatoid arthritis (RA) is a common disease in the department of rheumatology and immunology, and the basic pathology is manifested as synovitis, vascular filament formation, and gradual destruction of joint cartilage and bone, which eventually leads to joint deformity and loss of function, which seriously affects the patient's physical function and quality of life ^[1

The triggers for CVD in patients with RA can be divided into two broad categories, namely traditional risk factors and non-traditional risk factors

In January 2017, the European Federation against Rheumatism (EULAR) updated its recommendations for CVD risk management in patients with RA and other inflammatory joint ^{diseases [7].

Systemic inflammation plays an important role in the development of CVD in patients with RA, and therapeutic drugs targeting inflammatory mediators may reduce the risk

The data suggest that patients with RA treated with b/tsDMARDs have a generally lower

Multiple studies have shown that abatacept may be more effective at reducing the risk of CVD in patients with RA than csDMARDs and TNF inhibitors

In the process of clinical practice, it is necessary to consider the specific situation of patients with different RA, and select DMARDs with different mechanisms of action for patients with different risk factors to reduce the risk

Expert Profile
Professor Zhu Jing

Director of the Department of Rheumatology and Immunology, Sichuan Provincial People's Hospital
Chief Physician Master Tutor
President of the Rheumatology and Immunology Branch of Sichuan Medical Doctor Association
Chairman of the Rheumatology Committee of sichuan Medical Health and Health Promotion Association
Vice Chairman of the Rheumatology and Immunology Branch of Sichuan Medical Association
Member of the Standing Committee of the Rheumatology Physician Branch of the Chinese Medical Doctor Association
Member of the Standing Committee of the Rheumatology and Immunology Committee of the Cross-Strait Medical and Health Exchange Association, Deputy Leader of the Science Popularization Education Group, and Member of the Standing Committee of the Chronic Disease Management Group

References[1]Rheumatology Branch of Chinese Medical Association.
2018 Chinese Rheumatoid Arthritis Diagnosis and Treatment Guidelines[J].
Chin J Internal Medicine, 2018, 57(4):10.

[2]Dijkshoorn B, Raadsen R, Nurmohamed MT.
Cardiovascular Disease Risk in Rheumatoid Arthritis Anno 2022[J].
J Clin Med.
2022, 11(10): 2704.

[3]Chen YJ, Liu SC, Lai KL, et al.
Factors associated with risk of major adverse cardiovascular events in patients with rheumatoid arthritis: a nationwide, population-based, case-control study[J].
Ther Adv Musculoskelet Dis.
2021, 13:1759720X211030809.

[4]Fragoulis GE, Soulaidopoulos S, Sfikakis PP, et al.
Effect of Biologics on Cardiovascular Inflammation: Mechanistic Insights and Risk Reduction[J].
J Inflamm Res.
2021, 14:1915-1931.

[5]Singh S, Fumery M, Singh AG, et al.
Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis[J].
Arthritis Care Res (Hoboken).
2020; 72(4):561-576.

[6]Zhang J, Xie F, Yun H, et al.
Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis[J].
Ann Rheum Dis.
2016; 75(10):1813-1818.

[7]I.
J.
Berg, S.
Lillegraven, E.
Kristianslund, et al.
NOT ALL THE SAME? REACHING REMISSION REDUCES THE RISK OF CVD IN PATIENTS WITH RA, BUT PATIENTS ON BIOLOGICS MAY BE BETTER PROTECTED[J].
EULAR 2020.
Abstract number: OP0119.

[8]Agca R, Heslinga SC, Rollefstad S, et al.
EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update[J].
Ann Rheum Dis.
2017, 76(1):17-28.

[9]in Y, Kang EH, Brill G, et al.
Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease[J].
J Rheumatol.
2018, 45(9):1240-1248.

[10]Kang EH, Jin Y, Brill G, et al.
Comparative Cardiovascular Risk of Abatacept and Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis With and Without Diabetes Mellitus: A Multidatabase Cohort Study[J].
J Am Heart Assoc.
2018, 7(3): e007393.

[11]Ozen G, Pedro S, Michaud K.
The Risk of Cardiovascular Events Associated With Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis[J].
J Rheumatol.
2021, 48(5): 648-655.

[12]Singh S, Fumery M, Singh AG, et al.
Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis[J].
Arthritis Care Res (Hoboken).
2020, 72(4):561-576.

[13]Hsieh MJ, Lee CH, Tsai ML, et al.
Biologic Agents Reduce Cardiovascular Events in Rheumatoid Arthritis Not Responsive to Tumour Necrosis Factor Inhibitors: A National Cohort Study[J].
Can J Cardiol.
2020, 36(11):1739-1746.

[14]Ursini F, Russo E, Letizia Hribal M, et al.
Abatacept improves whole-body insulin sensitivity in rheumatoid arthritis: an observational study[J].
Medicine (Baltimore).
2015, 94(21): e888.

[15]Galiuto L, Patrono C.
Differential cardiovascular effects of disease-modifying antirheumatic drugs in rheumatoid arthritis[J].
Eur Heart J.
2022, 43(17):1615-1616.

[16]Atzeni F, Rodríguez-Carrio J, Popa CD, et al.
Cardiovascular effects of approved drugs for rheumatoid arthritis[J].
Nat Rev Rheumatol.
2021, 17(5):270-290.

[17]England BR, Thiele GM, Anderson DR, et al.
Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications[J].
BMJ.
2018, 361: k1036.

[18]Wang Q, Zhang M, Wang M, et al.
Triggers of Cardiovascular Diseases in Rheumatoid Arthritis[J].
Curr Probl Cardiol.
2021, 100853.

[19]Fazeli MS, Khaychuk V, Wittstock K, et al.
Cardiovascular Disease in Rheumatoid Arthritis: Risk Factors, Autoantibodies, and the Effect of Antirheumatic Therapies[J].
Clin Med Insights Arthritis Musculoskelet Disord.
2021, 14: 11795441211028751.
This article is only used to provide scientific information to healthcare professionals and does not represent the position of the
Platform.}

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.